Compare · DXCM vs NVCR
DXCM vs NVCR
Side-by-side comparison of DexCom Inc. (DXCM) and NovoCure Limited (NVCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and NVCR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $30.17B, about 15.1x NVCR ($2.00B).
- Over the past year, DXCM is down 7.8% and NVCR is down 6.1% - NVCR leads by 1.7 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 18 for NVCR).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- NovoCure Limited
- Price
- $78.19+2.08%
- $17.26+2.49%
- Market cap
- $30.17B
- $2.00B
- 1M return
- +29.01%
- -3.47%
- 1Y return
- -7.79%
- -6.14%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2015
- News (4w)
- 26
- 18
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest NVCR
- NovoCure Limited filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Stafford Kristin was granted 11,610 units of Ordinary Shares, increasing direct ownership by 103% to 22,934 units (SEC Form 4)
- Chief Executive Officer Leonard Frank X sold $614,635 worth of Ordinary Shares (34,273 units at $17.93), decreasing direct ownership by 7% to 459,520 units (SEC Form 4) (withholding tax)
- Director Leung Gabriel was granted 11,610 units of Ordinary Shares, increasing direct ownership by 13% to 101,109 units (SEC Form 4)
- Director Ocean Allyson J was granted 11,610 units of Ordinary Shares, increasing direct ownership by 103% to 22,934 units (SEC Form 4)
- Director Scannell Timothy J was granted 11,610 units of Ordinary Shares, increasing direct ownership by 81% to 25,898 units (SEC Form 4)
- Director Hilleman Jeryl L was granted 11,610 units of Ordinary Shares, increasing direct ownership by 84% to 25,471 units (SEC Form 4)
- Director Hung David was granted 11,610 units of Ordinary Shares, increasing direct ownership by 57% to 32,075 units (SEC Form 4)
- Director Madden Martin J. was granted 11,610 units of Ordinary Shares, increasing direct ownership by 62% to 30,284 units (SEC Form 4)
- Director Vernon W Anthony was granted 11,610 units of Ordinary Shares, increasing direct ownership by 6% to 209,267 units (SEC Form 4)